Introduction
============

Total knee arthroplasty (TKA) has been associated with severe postoperative pain, especially during the first 48 hours after surgery[@b1-ksrr-30-133],[@b2-ksrr-30-133]. Several multimodal analgesic regimens including peripheral nerve blocks have been proposed for effective postoperative pain control after TKA[@b3-ksrr-30-133]--[@b6-ksrr-30-133]. Although femoral nerve block (FNB), a widely used peripheral nerve block, provided a very satisfied postoperative pain control, it could accentuate quadriceps muscle weakness and contribute to a higher rate of falls at early ambulation[@b7-ksrr-30-133]. Therefore, the optimal multimodal analgesic regimens following TKA should offer a well balance between adequate pain control and sufficient lower motor function, especially preserved quadriceps strength to allow for safe early ambulation.

Currently, two methods of multimodal analgesia have become popular. The adductor canal block (ACB), a blockade of the saphenous nerve and/or the cutaneous branches of the femoral nerve in the adductor canal, has been proposed as an optional peripheral nerve block in multimodal analgesic regimen[@b8-ksrr-30-133]--[@b11-ksrr-30-133] with its superiority to FNB, in terms of negative effect on quadriceps strength. However, it innervated nerves that serve sensory function in only the anterior part of the knee capsule[@b12-ksrr-30-133],[@b13-ksrr-30-133]. The local infiltration analgesia (LIA), has been introduced to become a major part of pain control regimens for TKA due to its simplicity and apparent safety. However, rebound and severe postoperative analgesia after LIA effect wears off has been observed; therefore, it may not be an effective single analgesia[@b14-ksrr-30-133]--[@b19-ksrr-30-133]. The recent studies demonstrated that the addition of LIA to peripheral nerve block provided better pain relief and less opioid consumption after TKA than peripheral nerve block alone or LIA alone[@b20-ksrr-30-133]--[@b22-ksrr-30-133]. However, the clinical advantage of LIA in supplement to peripheral nerve block, especially ACB, remains unclear.

The objective of the present study was to determine the benefit of the addition of single- dose LIA to a single-injection ACB compared with ACB alone on functional ability and pain after TKA. We hypothesized that there would be no difference between the combination of ACB with single-dose LIA and single-injection ACB alone with regard to accelerating ambulation ability and improving postoperative pain after TKA.

Materials and Methods
=====================

1. Study Design
---------------

This single-center, randomized, placebo-controlled, double-blind trial study was approved by the Institutional Review Board and was registered with Clinicaltrials.in.th, identifier TCTR20150720006. From April 2015 to April 2016, 71 patients scheduled to undergo uncomplicated unilateral TKA were enrolled in this study. Inclusion criteria were patients aged more than 18 years with the American Society of Anesthesiologists (ASA) physical status I to III. Exclusion criteria were contraindication for neuraxial and/or regional anesthesia, history of allergy to drugs implicated in this study, chronic pain requiring opioid medication, neuropathic pain, failure in the preoperative Timed Up and Go (TUG) test, and subject refusal.

All patients were randomized to receive either a combined ACB and LIA mixture (group A+L) or ACB and 0.9% saline as a placebo (group A) using a computer generated random number table. The concealed assignments were opened in the operation room and one uninvolved anesthesiologist was assigned to prepare the LIA mixture and placebo. All patients were scheduled to undergo surgery in the morning as the first case of the day under a simple spinal analgesia using 0.5% hyperbaric bupivacaine 3 mL. All surgeries were performed by 2 senior surgeons using a single surgical technique (mini-midvastus approach) with a tourniquet pressure of 320 mmHg. A single total knee prosthesis, NexGen posterior stabilized knee system (NexGen-LPS; Zimmer, Warsaw, IN, USA), was used in all knees. After surgery, the tourniquet was not deflated for hemostasis. The vacuum drain was inserted and removed 18--22 hours after surgery.

Before wound closure, both senior surgeons who performed surgeries were blinded to injection of LIA mixture or placebo. The LIA mixture, which contained the same concentration of morphine according to the first study using LIA in TKA of Busch et al.[@b16-ksrr-30-133] (0.5% levobupivacaine 20 mL, morphine 5 mg, adrenaline 0.3 mg in saline solution in a total volume of 100 mL), was injected into synovial tissue and joint capsule around the knee joint. Then, a single-dose ACB was performed in all patients at the recovery unit. After identification of the adductor canal at the midthigh level using a high-frequency linear ultrasound transducer (10--12 Hz; SonoSite Turbo, SonoSite Inc., Bothell, WA, USA), a total of 0.5% levobupivacaine 20 mL was injected into the adductor canal by using a 22-guage, 100 mm needle (Stimuplex; B Braun, Bethlehem, PA, USA). All patients received a premedication of acetaminophen 650 mg at 30 minutes before surgery. Dexamethasone 10 mg and ondansetron 4 mg were administered intravenously in all patients for postoperative nausea and vomiting prophylaxis.

Regarding pain rescue, all patients received a patient-controlled analgesia (PCA) device for 48 hours postoperatively, with morphine 2 mg/dose, 10-minute lockout time and no basal infusion. In all patients, intravenous parecoxib (Dynastat) 40 mg was administered every 12 hours for 3 consecutive doses starting at the recovery unit, and oral daily celecoxib (Celebrex) 400 mg was continued after the last dose of parecoxib. Oral Acetaminophen 650 mg every 6 hours was started at the patient ward for 1 day. Daily esomeprazole (Nexium) 40 mg was started from the night of postoperative day 0. Daily pregabalin (Lyrica) 75 mg was started from the night of postoperative day 1. Metoclopramide 5 mg was administered intravenously for rescuing nausea and vomiting and chlorpheniramine 5 mg was administered intravenously to reduce itching.

2. Outcome Measures
-------------------

Preoperatively, patients were instructed for pre- and postoperative ambulation ability assessment, quadriceps strength test and visual analog scale (VAS) score. Demographic characteristics, preoperative VAS score, TUG test and quadriceps strength were serially recorded. The TUG test was defined by measuring the time to rise from an arm chair (seat height at 46 cm), walk for 3 m, turn, and return to sitting in the same chair without physical assistance[@b23-ksrr-30-133]. Quadriceps strength test was performed according to the method of Judd et al.[@b24-ksrr-30-133] using an isometric force dynamometer (MicroFET2; Hoggan Scientific, Salt Lake City, UT, USA).

From the morning of postoperative day 1 from 7 to 8 am, all patients were encouraged to sit, straighten both legs, stand up and walk using a walker as tolerated. All patients were allowed to ambulate independently with walking aid until discharge. Discharge criteria included stable vital signs, good appetite, no local wound problems, full weight bearing on the operated limb, and 90° knee flexion. All patients were prescribed oral medications, including ultracet 0.5 tab twice a day, daily celecoxib 200 mg, daily pregabalin 75 mg, and daily esomeprazole 20 mg for 2 weeks. Tramadol 50 mg was prescribed for pain rescue as needed every 6 hours.

A serial evaluation of postoperative pain was conducted at rest and at movement using VAS from postoperative day 1 to day 3, and then at 2 weeks, 6 weeks, and 3 months by an independent evaluator. The Knee Society System (KSS) clinical and function scores of both groups were evaluated at 6 months and 1 year.

The morphine consumptions via PCA device were recorded for the first time of requirement and at 3, 12, 24 and 48 hours postoperatively. Similarly, the TUG test and the quadriceps strength test were also serially recorded by an independent physiotherapist.

3. Sample Size and Statistical Analysis
---------------------------------------

In a pilot study of 10 patients who received spinal anesthesia combined with ACB alone, the mean time for TUG test on postoperative day 2 was 92.5±26.5 seconds. We assumed that a 25% reduction should be considered clinically significant. For a non-inferiority or superiority trial with continuous outcome, we calculated that 28 patients in each group were required to detect a mean difference of 23.1 seconds with standard deviation of 26.4 seconds on the TUG test using the *t*-test (independent samples), α=0.05 and a power of 80%. We planned for an inclusion of 31 patients to compensate for dropouts.

Statistical analysis was performed by using IBM SPSS ver. 22.0 (IBM Corp., Armonk, NY, USA). Repeated measures analysis of variance were used for the analysis of TUG test and VAS. Categorical data were analyzed by using the chi-square test or Fisher exact test. Normal distributed data were statistically tested with the independent *t*-test, and data that did not fulfill the assumptions of normal distribution were analyzed with the Mann-Whitney *U*-test. The paired *t*-test was used to compare a within-subjects test group before and after an intervention. A p-value of less than 0.05 was considered to be statistically significant.

Results
=======

Patient recruitment and flow through the protocol are described in the Consolidated Standards of Reporting Trials (CONSORT) diagram ([Fig. 1](#f1-ksrr-30-133){ref-type="fig"}). Nine patients were excluded from the study due to patient's impaired compliance and disagreement to continue. Therefore, 62 patients were randomized and evaluated. At early follow-up, 60 patients (30 in group A+L and 30 in group A) were available for complete evaluation; however, at 1-year follow-up, 2 patients in group A+L and 1 patient in group A were not able for clinical evaluation. Demographic data, duration of surgery, preoperative TUG test, preoperative quadriceps strength, and length of hospital stay of both groups were not significantly different ([Table 1](#t1-ksrr-30-133){ref-type="table"}).

There were no differences of postoperative VAS on postoperative day 1 to day 3 and at all points of follow-up between both groups as shown in [Table 2](#t2-ksrr-30-133){ref-type="table"}. The median time to request the first analgesic was significantly longer in group A+L than group A with a significantly lower percentage of patients requiring rescue analgesia at a duration of 6 hours after surgery. However, at a duration of 12 hours after surgery, both groups had similar percentages of patients requiring rescue analgesia, and the overall morphine consumption of both groups at 24 and 48 hours were not significantly different ([Table 3](#t3-ksrr-30-133){ref-type="table"}). There were similarly low incidences of nausea/vomiting and pruritus between groups ([Table 4](#t4-ksrr-30-133){ref-type="table"}). No patient's falls were recorded in either arm during the study period.

There were no differences in TUG test between both groups at all points of follow-up as shown in [Fig. 2](#f2-ksrr-30-133){ref-type="fig"}. However, in comparison to the preoperative evaluation, both groups had significantly extended time of postoperative TUG test, which returned to a similar value of the preoperative period at 6-week follow-up. The postoperative quadriceps strengths during knee full extension, 45° flexion, and 90° flexion on postoperative days 2 and 3 were similar between both groups at all points of follow-up as shown in [Fig. 3](#f3-ksrr-30-133){ref-type="fig"}. The overall patient satisfaction rates of group A+L and group A were 89% and 88%, respectively, showing no intergroup difference. There were differences in KSS clinical and function scores at 6 months and 1 year of follow-up as shown in [Table 5](#t5-ksrr-30-133){ref-type="table"}. There was no readmission or no revision for any reasons in this study.

Discussion
==========

The present randomized, placebo-controlled study was conducted to evaluate the benefit of the addition of LIA to a single-dose ACB compared to single-dose ACB alone on postoperative pain, early ambulation ability, and quadriceps strength after TKA, which resulted in similar VAS, TUG test, and quadriceps strength at all points of measurement, as well as similarly low total morphine consumption and adverse reactions and high patient satisfaction rates in both groups. These findings imply that both regimens of multimodal pain control were similarly effective without interference of quadriceps strength which was found related to FNB[@b7-ksrr-30-133].

Significant advantages of combined LIA with single-dose ACB included delaying the time for the first request of rescue analgesia with less patients requiring rescue analgesia during 6 postoperative hours. These results might be due to the ability of the LIA to provide local analgesia into the entire area of soft tissue around the surgical site, which could contribute to greater analgesia than only the use of ACB. However, the effect of the combination treatment may have not persisted longer than 6--8 hours postoperatively after TKA. These results are consistent with prior studies[@b9-ksrr-30-133],[@b17-ksrr-30-133] that showed the duration of the ACB (20--22 hours) was longer than the LIA (6--12 hours) for postoperative analgesia. Therefore, there was no difference in pain score and morphine consumption after 12 hours postoperatively between groups in this study. In addition, the primary outcome (TUG test on postoperative day 2) was not significantly different between the two groups. It might possibly be due to several reasons including very low levels of postoperative pain after TKA, resulting in no or minimal effects on pain on ambulation in both groups, as well as inter- or intrapersonal variabilities such as physiotherapist-patient coordination or patient anxiety when TUG test was measured.

Disadvantages of these combined LIA and single-dose ACB can be described as technically demanding and time consuming. To improve the efficiency of these combined procedures, the anesthesiologist should have adequate practice in order to develop consistent skills to perform a reliable ACB under ultrasound guidance in limited time.

The results of the present study disagree with the studies of Koh et al.[@b20-ksrr-30-133] and Sawhney et al.[@b25-ksrr-30-133]. These studies reported superior analgesic effect of combined ACB and LIA than ACB alone or LIA alone on postoperative mobility after TKA. Contrary to their study which used nonsteroidal anti-inflammatory drug (NSAID) only in the LIA group, the present study used NSAID in both groups which might be related to the similarly satisfactory pain control and very low total morphine consumption for rescue analgesia in both groups. A recent study has shown that NSAID adjuvants in LIA mixture or systemic administration enhanced less opioid consumption and provided earlier mobilization and hospital discharge than those methods without NSAID[@b26-ksrr-30-133]. Therefore, the positive analgesic effect of parecoxib in the present study might have played a role in multimodal pain control, minimizing the total morphine consumption in both groups.

The assessment of the efficacy of the LIA and the ACB might be obscured by the effect of spinal analgesia. However, spinal analgesia in the present study was designed to use only bupivacaine. Therefore, its effect generally does not persist more than 1--1.5 hours after surgery. Moreover, we used the similar dose of intrathecal bupivacaine and postoperative multimodal analgesia protocol in all patients. Therefore, these factors should have caused minimal to no conflicts in this study. The serial postoperative TUG tests and the quadriceps strength tests from postoperative day 2 were significantly worse than those of preoperative period. These findings are in agreement with several previous studies[@b27-ksrr-30-133]--[@b29-ksrr-30-133], in which performance-based measures after TKA were impaired for a minimum of 6 weeks postoperatively until they gradually returned to show significant improvement.

Our study has some limitations. Firstly, the present study injected 100 mL of LIA mixture in group A+L, which seemed to be less than that in several studies. However, the overall amount of anesthetic agent and other cocktail agents were calculated based on patient's body weight and proper doses. Therefore, we limited only the total volume of the cocktail mixture. The 100-mL volume was also considered appropriate for most of our patients who had small statures and small knees, which resulted in significantly extended time for the first morphine pain rescue and a lower percentage of patients who required pain rescue medication. Lastly, the LIA mixture contained morphine which might have affected the delay in requiring rescue doses of morphine via PCA. However, morphine used in the LIA mixture in the present study was not different from that in previous several studies[@b16-ksrr-30-133],[@b26-ksrr-30-133]--[@b27-ksrr-30-133],[@b30-ksrr-30-133] which compared different anesthetic techniques in TKA and reported on morphine consumption and side effects for pain rescue as their outcomes.

Conclusions
===========

Although combined LIA and single-dose ACB under simple spinal analgesia in TKA provided similarly low level of postoperative pain, early ambulation ability, quadriceps strength at all points of measurement, and total morphine consumption, compared to single-dose ACB alone, combined LIA and single-dose ACB significantly reduced and delayed the first request for rescue analgesia after surgery.
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###### 

Patient Characteristics

  Parameter                      Group A (n=30)   Group A+L (n=30)   p-value
  ------------------------------ ---------------- ------------------ ---------
  Age (yr)                       72.37±8.02       69.1±5.36          0.069
  Gender                                                             
   Male                          3 (10)           4 (13.3)           1
   Female                        27 (90)          26 (86.7)          
  Body mass index (kg/m^2^)      26.25±3.72       27.92±4.64         0.13
  ASA classification                                                 
   ASA 1                         0 (0)            0 (0)              1
   ASA 2                         29 (96.7)        28 (93.3)          
   ASA 3                         1 (3.3)          2 (6.7)            
   ASA 4                         0 (0)            0 (0)              
  Side                                                               
   Left                          16 (53.3)        16 (53.3)          1
   Right                         14 (46.7)        14 (46.7)          
  Preoperative evaluation                                            
   VAS at rest                   3.2±2.1          3.6±2.0            0.48
   VAS at movement               7.4±2.4          7.5±2.5            0.67
  Quadriceps strength (N/m^2^)                                       
   Knee full extension           98.41±43.11      104.02±42.31       0.61
   45° flexion                   129.56±61.99     125.31±54.95       0.78
   90° flexion                   119.72±56.36     120.05±53.23       0.98
  Surgical time (min)            119.47±25.76     112.83±28          0.34
  Hospital stay (day)            4±0              4±0                1

Values are presented as mean±standard deviation or number (%).

Group A: adductor canal block group, Group A+L: adductor canal block combined with local infiltration analgesia group, ASA: American Society of Anesthesiologists, VAS: visual analog scale.

###### 

Visual Analog Scale (VAS) from Postoperative Day 0 to Day 3

  Parameter           Group A     Group A+L   p-value
  ------------------- ----------- ----------- ---------
  VAS POD 0                                   
   6 hours            1.94±1.74   1.23±1.17   0.07
   12 hours           1.29±2.03   0.84±0.85   0.28
   18 hours           1.46±1.7    1.45±1.3    0.97
  VAS POD 1 at 8 am                           
   Rest               1.49±1.60   1.05±1.02   0.21
   Sit                1.88±1.64   1.78±1.15   0.79
   Knee flexion       2.89±1.59   2.43±1.42   0.25
   Knee extension     2.36±1.76   2.26±1.26   0.80
  VAS POD 2 at 8 am                           
   Rest               1.23±1.30   1.94±1.51   0.06
   Sit                1.93±1.75   2.50±1.18   0.14
   Stand              2.50±2.01   3.24±1.31   0.10
   Walk               2.58±1.8    3.27±1.46   0.11
  VAS POD 3 at 8 am                           
   Rest               1.36±1.34   1.65±1.26   0.38
   Sit                1.66±1.45   2.15±1.32   0.17
   Stand              1.94±1.36   2.62±1.71   0.09
   Walk               2.22±1.36   2.55±1.65   0.40

Values are presented as mean±standard deviation.

Group A: adductor canal block group, Group A+L: adductor canal block combined with local infiltration analgesia group, POD: postoperative day.

###### 

Time to First Request for Rescue Analgesia and Morphine Consumption

  Parameter                                    Group A (n=30)   Group A+L (n=30)   p-value
  -------------------------------------------- ---------------- ------------------ ---------
  Duration to the 1st morphine request (min)   143              490.5              0.040
   Shortest time                               105              150                
   Longest time                                498              1,090              
  Patients who requested morphine, no. (%)                                         
   At ≤6 hours                                 13 (43.3)        5 (16.7)           0.024
  Morphine consumption (mg), mean (range)                                          
   Up to 12 hours                              4 (0--8)         2 (0--4)           0.15
   Up to 24 hours                              6 (0--14)        4 (0--8)           0.30
   Up to 47 hours                              10 (4--20)       9 (4--18)          0.84

Group A: adductor canal block group, Group A+L: adductor canal block combined with local infiltration analgesia group.

###### 

Adverse Events from Postoperative Day 1 to Day 3

  Parameter                Group A (n=30)   Group A+L (n=30)   p-value
  ------------------------ ---------------- ------------------ ---------
  Overall fall             0 (0)            0 (0)              1.00
  Nausia and vomiting                                          
   POD 1                                                       
    None                   24 (80)          17 (56.7)          0.06
    Queasy                 3 (10)           6 (20)             
    Severe nausea          0 (0)            5 (16.7)           
    Vomiting               3 (10)           2 (6.7)            
   POD 2                                                       
    None                   24 (80)          23 (76.7)          0.95
    Queasy                 5 (16.7)         6 (20)             
    Severe nausea          1 (3.3)          1 (3.3)            
    Vomiting               0 (0)            0 (0)              
   POD 3                                                       
    None                   26 (86.7)        19 (63.3)          0.13
    Queasy                 2 (6.7)          8 (26.7)           
    Severe nausea          0 (0)            1 (3.3)            
    Vomiting               0 (0)            0 (0)              
  Pruritus                                                     
   POD 1                                                       
    None                   22 (73.3)        19 (63.3)          0.10
    Mild & no treatment    5 (16.7)         9 (30)             
    Moderate & treatment   3 (10)           0 (0)              
    Severe & treatment     0 (0)            2 (6.7)            
   POD 2                                                       
    None                   21 (70)          25 (83.3)          0.20
    Mild & no treatment    9 (30)           4 (13.3)           
    Moderate & treatment   0 (0)            1 (3.3)            
    Severe & treatment     0 (0)            0 (0)              
   POD 3                                                       
    None                   27 (90)          28 (93.3)          1.00
    Mild & no treatment    3 (10)           2 (6.7)            
    Moderate & treatment   0 (0)            0 (0)              
    Severe & treatment     0 (0)            0 (0)              

Values are presented as number (%).

Group A: adductor canal block group, Group A+L: adductor canal block combined with local infiltration analgesia group, POD: postoperative day.

###### 

KSS Clinical and Function Scores

  Parameter                          Group A     Group A+L   p-value
  ---------------------------------- ----------- ----------- ---------
  Follow-up (mo)                     15.3        15.7        \>0.05
  Preop KSS clinical score (point)   34.3 (30)   34.7 (30)   \>0.05
  Preop KSS function score (point)   32.2 (30)   31.8 (30)   \>0.05
  Six-month follow-up (point)                                
   KSS clinical score                84.3 (29)   84.5 (30)   \>0.05
   KSS function score                72.9 (29)   72.8 (30)   \>0.05
  One-year follow-up (point)                                 
   KSS clinical score                92.1 (29)   92.9 (28)   \>0.05
   KSS function score                89.7 (29)   89.5 (28)   \>0.05

Values are presented as mean (number).

Group A: adductor canal block group, Group A+L: adductor canal block combined with local infiltration analgesia group, Preop: preoperative, KSS: Knee Society System.
